The safe use of the CredibleMeds® lists of medications requires that the user have the most up-to-date lists and be aware when changes are made to the lists. Therefore, we wish to inform you of the following changes. We have reviewed the available evidence for ezogabine (an anticonvulsant also known as retigabine) (brand name Potiga® or Trobalt®) and found convincing evidence that it can prolong the QT interval. We have therefore added it to the list of drugs with Possible Risk of TdP.
We have also found evidence that the antiviral drug atazanavir (brand name Reyataz®), now on our Possible Risk list, is associated with TdP when taken with other drugs that prolong the QT interval. Therefore, we have moved it from the Possible Risk list to the Conditional Risk list.
These drugs are now on the list of Drugs to Avoid in patients with Congenital Long QT Syndrome (if at all possible).